Diabetes is a heterogeneous disease and different genetics and environmental factors are involved in this disease. Beta cells are destroyed in diabetes type I and hence no insulin is produced. One approach for diabetes type I treatment, which is now in preclinical stage, is cell therapy. The main purpose of this study is to increase the efficacy of diabetes type I cell therapy by nanocurcumin.